http://www.marketreportsonline.com/Market Reports Online XML Feedhttp://www.marketreportsonline.com/232562-suvorexant-key-pa.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers&nbsp; SuvorexantSuvorexant indications:&nbsp; Treatment of insomniaSuvorexant innovator: Merck (Suvorexant)Examples of information found in this online report include:Includes key patent publications for 44 countries&nbsp; (see list below)Contains SPC protection for every EU state plu...Fri, 05 Apr 2013 00:00:00 GMThttp://www.marketreportsonline.com/232644-insulin-aspart-ke.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers&nbsp; Insulin AspartInsulin Aspart indications:&nbsp; Treatment of diabetes mellitus, optionally in combination with a intermediate-acting or long-acting insulinInsulin Aspart innovator: Novo Nordisk (NovoRapid, NovoRapid Penfill, NovoRapid Innolet, Novorapid Flextouch, Novo Rapid Novolet, NovoMix, NovoMix ...Fri, 05 Apr 2013 00:00:00 GMThttp://www.marketreportsonline.com/232645-suvorexant--key-p.htmlPipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers&nbsp; Suvorexant Suvorexant&nbsp; indications:&nbsp; Treatment of insomniaSuvorexant&nbsp; innovator: Merck (Suvorexant)Examples of information found in this online report include:Includes key patent publications for 7 countries (see list below)Contains SPC protection for every EU state plu...Fri, 05 Apr 2013 00:00:00 GMThttp://www.marketreportsonline.com/232646-insulin-aspart-ke.htmlPipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers&nbsp; Insulin AspartInsulin Aspart indications:&nbsp; Treatment of diabetes mellitus, optionally in combination with a intermediate-acting or long-acting insulinInsulin Aspart innovator: Novo Nordisk (NovoRapid, NovoRapid Penfill, NovoRapid Innolet, Novorapid Flextouch, Novo Rapid Novolet, NovoMix, NovoMix ...Fri, 05 Apr 2013 00:00:00 GMThttp://www.marketreportsonline.com/218977-dapagliflozin-key.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers DapagliflozinDapagliflozin indications: Adjunctive therapy to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus, optionally in combination with glucose-lowering agents including Metformin, a sulfonylurea or InsulinDapagliflozin innovator: Bristol-Myers Squibb (Forxiga, Empliciti, Edistride, Appebb); AstraZeneca (Forxiga)</...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218976-canagliflozin-key.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers CanagliflozinCanagliflozin indications: Treatment of type 2 diabetes mellitus, optionally in combination with glucose-lowering agentsCanagliflozin innovator: JanssenExamples of information found in this online report include:# Includes key patent publications for 44 countries (see list below)# Contains SPC protection for every EU state pl...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218975-axitinib-key-pate.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers AxitinibAxitinib indications: Treatment of metastatic and advanced renal cell carcinoma after failure of one prior systemic therapyAxitinib innovator: Pfizer (Inlyta)Examples of information found in this online report include:# Includes key patent publications for 44 countries (see list below)# Contains SPC protection for every EU state p...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218974-dexmedetomidine-k.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers DexmedetomidineDexmedetomidine indications: Sedation of prior to and during surgical or other procedures; Sedation of intubated/mechanically ventilated ICU patients during treatmentDexmedetomidine innovator: Hospira (Precedex); Orion (Dexdor)Examples of information found in this online report include:# Includes key patent publications for 44 co...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218973-bendamustine-key-.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers BendamustineBendamustine indications: Treatment of patients with relapsed indolent B-cell non-Hodgkin lymphoma who did not respond to a Rituximab regimen; Treatment of symptomatic chronic lymphocytic leukaemia; Treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with PrednisoneBendamustine innovator: Lundbeck (Treanda...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218972-cefazolin-key-pat.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers CefazolinCefazolin indications: Treatment of respiratory tract infections, nasopharyngeal infections, genitourinary tract infections, skin and skin structure infections, biliary tract infections, bone and joint infections, septicemia, and endocarditis; Prophylaxis of postoperative infectionsCefazolin innovator: Eli Lilly (Kefzol, Kefol), Glaxosmithkline (Ancef)...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218971-ceftriaxone-key-p.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers CeftriaxoneCeftriaxone indications: Treatment of lower respiratory tract infections, skin and skin structure infections, urinary tract infections, uncomplicated gonorrhea, bacterial septicemic, bone and joint infections, intra-abdominal infections, meningitis, acute bacterial otitis media (middle ear infection) and pelvic inflammatory disease; Prophylaxis of postope...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218970-clindamycin-key-p.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers ClindamycinClindamycin indications: Treatment of serious infections caused by susceptible strains including bacterial vaginosis, lower respiratory tract infections, skin and skin structure infections, gynecological infections, intra-abdominal infections, bone and joint infections, septicemia, malaria and other protozoal diseases; Treatment of acne vulgaris optionall...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218969-dapagliflozin-key.htmlPipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers DapagliflozinDapagliflozin indications: Adjunctive therapy to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus, optionally in combination with glucose-lowering agents including Metformin, a sulfonylurea or InsulinDapagliflozin innovator: Bristol-Myers Squibb (Forxiga, Empliciti, Edistride, Appebb); AstraZeneca (Forxiga)</...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218968-canagliflozin-key.htmlPipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers CanagliflozinCanagliflozin indications: Treatment of type 2 diabetes mellitus, optionally in combination with glucose-lowering agentsCanagliflozin innovator: JanssenExamples of information found in this online report include:# Includes key patent publications for 7 countries (see list below)# Contains SPC protection for every EU state plus...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218967-axitinib-key-pate.htmlPipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers AxitinibAxitinib indications: Treatment of metastatic and advanced renal cell carcinoma after failure of one prior systemic therapyAxitinib innovator: Pfizer (Inlyta)Examples of information found in this online report include:# Includes key patent publications for 7 countries (see list below)# Contains SPC protection for every EU state plu...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218966-dexmedetomidine-k.htmlPipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers DexmedetomidineDexmedetomidine indications: Sedation of prior to and during surgical or other procedures; Sedation of intubated/mechanically ventilated ICU patients during treatmentDexmedetomidine innovator: Hospira (Precedex); Orion (Dexdor)Examples of information found in this online report include:# Includes key patent publications for 7 cou...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218965-bendamustine-key-.htmlPipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers BendamustineBendamustine indications: Treatment of patients with relapsed indolent B-cell non-Hodgkin lymphoma who did not respond to a Rituximab regimen; Treatment of symptomatic chronic lymphocytic leukaemia; Treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with PrednisoneBendamustine innovator: Lundbeck (Treanda...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218964-cefazolin-key-pat.htmlPipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers CefazolinCefazolin indications: Treatment of respiratory tract infections, nasopharyngeal infections, genitourinary tract infections, skin and skin structure infections, biliary tract infections, bone and joint infections, septicemia, and endocarditis; Prophylaxis of postoperative infectionsCefazolin innovator: Eli Lilly (Kefzol, Kefol), Glaxosmithkline (Ancef)...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218963-ceftriaxone-key-p.htmlPipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers CeftriaxoneCeftriaxone indications: Treatment of lower respiratory tract infections, skin and skin structure infections, urinary tract infections, uncomplicated gonorrhea, bacterial septicemic, bone and joint infections, intra-abdominal infections, meningitis, acute bacterial otitis media (middle ear infection) and pelvic inflammatory disease; Prophylaxis of postope...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/218962-clindamycin-key-p.htmlPipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers ClindamycinClindamycin indications: Treatment of serious infections caused by susceptible strains including bacterial vaginosis, lower respiratory tract infections, skin and skin structure infections, gynecological infections, intra-abdominal infections, bone and joint infections, septicemia, malaria and other protozoal diseases; Treatment of acne vulgaris optionall...Fri, 01 Feb 2013 00:00:00 GMThttp://www.marketreportsonline.com/207048-colesevelam--key-.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers Colesevelam Colesevelam indications: Adjucntive therapy to diet for reducing elevated low-density lipoprotein cholesterol (LDL-C) or cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa), optionally in combination with a HMG-CoA reductase inhibitor; Adjunctive therapy to diet and exercise for improving glycemic control in patients wi...Thu, 15 Nov 2012 00:00:00 GMThttp://www.marketreportsonline.com/207047-vemurafenib--key-.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers Vemurafenib Vemurafenib indications: Treatment of BRAF V600 mutation-positive unresectable or metastatic melanomaVemurafenib innovator: Roche (Zelboraf)Examples of information found in this online report include:# Includes key patent publications for 44 countries (see list below)# Contains SPC protection for every EU state plus patent t...Thu, 15 Nov 2012 00:00:00 GMThttp://www.marketreportsonline.com/207049-rifaximin-key-pat.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers RifaximinRifaximin indications: Treatment of traveller''s diarrhoea; Treatment of hepatic encephalopathy, optionally in combination with LactuloseRifaximin innovator: Norgine (Xifaxan, Xifaxanta); Salix (Xifaxan); Alfa Wassermann (Flonorm, Normix, Redactiv, Xifaxan); Formenti (Rifacol)Examples of information found in this online report include:<br/...Thu, 15 Nov 2012 00:00:00 GMThttp://www.marketreportsonline.com/207050-nevirapine-key-pa.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers Nevirapine Nevirapine indications: Treatment of HIV-1 infection in combination with other antiretroviral agents, such as Lamivudine, Stavudine, Zidovudine and TenofovirNevirapine innovator: Boehringer Ingelheim (Viramune, Viramune XR)Examples of information found in this online report include:# Includes key patent publications for 44 count...Thu, 15 Nov 2012 00:00:00 GMThttp://www.marketreportsonline.com/207051-liraglutide-key-p.htmlPipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.This Pipeline Selector report covers LiraglutideLiraglutide indications: Treatment of type 2 diabetes mellitus, optionally in combination with Metformin and/or a sulphonylureaLiraglutide innovator: Novo Nordisk (Victoza)Examples of information found in this online report include:# Includes key patent publications for 44 countries (see list below)# Contains SPC protection for...Thu, 15 Nov 2012 00:00:00 GMT